{"id":"neostigmine-and-glycopyrrolate-or-atropine","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Increased salivation"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Muscle fasciculations"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Neostigmine is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, thereby enhancing neuromuscular transmission. The co-administered anticholinergic agent (glycopyrrolate or atropine) blocks muscarinic acetylcholine receptors to mitigate unwanted parasympathomimetic effects such as excessive salivation, bronchospasm, and bradycardia while preserving the beneficial nicotinic effects at the neuromuscular junction.","oneSentence":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate or atropine blocks muscarinic receptors to prevent cholinergic side effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:54.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of neuromuscular blockade"},{"name":"Myasthenia gravis"}]},"trialDetails":[{"nctId":"NCT06948409","phase":"","title":"NMBA Reversal and Postoperative Urinary Retention","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2025-06-08","conditions":"Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative","enrollment":70000},{"nctId":"NCT03909165","phase":"PHASE4","title":"Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-07-23","conditions":"Neuromuscular Blockade","enrollment":145},{"nctId":"NCT01422304","phase":"PHASE3","title":"Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-12","conditions":"Neuromuscular Blockade, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee","enrollment":1198},{"nctId":"NCT03351608","phase":"PHASE4","title":"Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-12","conditions":"Neuromuscular Blockade","enrollment":288},{"nctId":"NCT03034577","phase":"PHASE4","title":"Deep Neuromuscular Block for Laparoscopic Surgery","status":"COMPLETED","sponsor":"University of Melbourne","startDate":"2017-06-16","conditions":"Laparoscopy, Anesthesia Recovery Period","enrollment":350},{"nctId":"NCT02327923","phase":"PHASE4","title":"Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2015-01","conditions":"Gall Stone Disease","enrollment":90},{"nctId":"NCT02878512","phase":"PHASE4","title":"Segmental Epidural Anesthesia (SEA) V/S General Anesthesia for PCNL","status":"COMPLETED","sponsor":"Maharashtra University of Health Sciences","startDate":"2009-06","conditions":"Success Rate Under Segmental Epidural, Post Operative Pain","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"neostigmine and glycopyrrolate or atropine","genericName":"neostigmine and glycopyrrolate or atropine","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate or atropine blocks muscarinic receptors to prevent cholinergic side effects. Used for Reversal of neuromuscular blockade, Myasthenia gravis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}